These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32661791)

  • 1. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.
    De Pascale G; Lisi L; Ciotti GMP; Vallecoccia MS; Cutuli SL; Cascarano L; Gelormini C; Bello G; Montini L; Carelli S; Di Gravio V; Tumbarello M; Sanguinetti M; Navarra P; Antonelli M
    Ann Intensive Care; 2020 Jul; 10(1):94. PubMed ID: 32661791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
    De Pascale G; Montini L; Pennisi M; Bernini V; Maviglia R; Bello G; Spanu T; Tumbarello M; Antonelli M
    Crit Care; 2014 May; 18(3):R90. PubMed ID: 24887101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial.
    Benítez-Cano A; Luque S; Sorlí L; Carazo J; Ramos I; Campillo N; Curull V; Sánchez-Font A; Vilaplana C; Horcajada JP; Adalia R; Bermejo S; Samsó E; Hope W; Grau S
    Crit Care; 2020 Feb; 24(1):55. PubMed ID: 32066497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
    Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum and peritoneal exudate concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study.
    Leon L; Guerci P; Pape E; Thilly N; Luc A; Germain A; Butin-Druoton AL; Losser MR; Birckener J; Scala-Bertola J; Novy E
    J Antimicrob Chemother; 2020 Jan; 75(1):156-161. PubMed ID: 31599951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx).
    Alraish R; Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Wuensch T; Kaffarnik M
    Ann Intensive Care; 2020 Aug; 10(1):106. PubMed ID: 32754775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of tigecycline in critically ill patients.
    Luo X; Wang S; Li D; Wen J; Sun N; Fan G
    Front Pharmacol; 2023; 14():1083464. PubMed ID: 36992827
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections.
    Ruiz J; Ramirez P; Villarreal E; Gordon M; Sánchez MÁ; Martín M; Castellanos-Ortega Á
    SAGE Open Med; 2020; 8():2050312120958897. PubMed ID: 32999720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 12. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.
    Gotfried MH; Horn K; Garrity-Ryan L; Villano S; Tzanis E; Chitra S; Manley A; Tanaka SK; Rodvold KA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
    Geng TT; Xu X; Huang M
    Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia.
    Zhou Y; Xu P; Li H; Wang F; Yan H; Liang W; Xiang D; Zhang B; Banh HL
    Br J Clin Pharmacol; 2021 Jul; 87(7):2838-2846. PubMed ID: 33283892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database.
    Logre E; Enser M; Tanaka S; Dubert M; Claudinon A; Grall N; Mentec H; Montravers P; Pajot O
    Ann Intensive Care; 2020 Jun; 10(1):75. PubMed ID: 32514769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Bader JC; Lakota EA; Dale GE; Sader HS; Rex JH; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
    Conte JE; Golden JA; Kelly MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.